REFERENCES
- Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic
syndrome: a multicenter, retrospective analysis of clinical
characteristics and response to therapy. J Allergy Clin
Immunol. 2009;124(6):1319-25.e3.
- Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of
myeloproliferative hypereosinophilic syndrome in the United States and
an estimate of all hypereosinophilic syndrome incidence. J
Allergy Clin Immunol. 2010;126(1):179-81.
- Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E.
Eosinophilic Myocarditis: Characteristics, Treatment, and
Outcomes. J Am Coll Cardiol. 2017;70(19):2363-75.
- Mankad R, Bonnichsen C, Mankad S. Hypereosinophilic syndrome: cardiac
diagnosis and management. Heart. 2016;102(2):100-6.
- Young J.D., Peterson C.G., Venge P., et al: Mechanism of membrane
damage mediated by human eosinophil cationic protein. Nature 1986;
321: pp. 613
- Ruggeri ZM. Platelet interactions with vessel wall components during
thrombogenesis. Blood Cells Mol Dis. 2006;36(2):145-7.
- Curtis C, Ogbogu P. Hypereosinophilic Syndrome. Clin Rev Allergy
Immunol. 2016;50(2):240-51.
- Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac
Troponin T in patients with hypereosinophilic syndrome treated with
imatinib is predictive of adverse
outcomes. Blood. 2003;102(9):3456-7; author reply 3457.
- Morimoto S, Kubo N, Hiramitsu S, et al. Changes in the peripheral
eosinophil count in patients with acute eosinophilic
myocarditis. Heart Vessels. 2003;18(4):193-6.
- Lim J, Sternberg A, Manghat N, Ramcharitar S. Hypereosinophilic
syndrome masquerading as a myocardial infarction causing decompensated
heart failure. BMC Cardiovasc Disord. 2013;13:75.
- Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular
magnetic resonance in myocarditis: A JACC White Paper. J Am Coll
Cardiol. 2009;53(17):1475-87.
- Yanagisawa T, Inomata T, Watanabe I, et al. Clinical significance of
corticosteroid therapy for eosinophilic myocarditis. Int Heart
J. 2011;52(2):110-3.